Biogen litifilimab CLE data show durable skin clearance at 52 weeks
Biogen has published 52-week Phase 2 results from its ongoing AMETHYST Phase 2/3 study of litifilimab in cutaneous lupus erythematosus (CLE), reporting continued improvement in skin clearance beyond the 24-week mark and no new safety signals. The data were presented at the European Academy of Dermatology and Venereology Congress in Vienna on 2 October 2026 and represent the longest dataset yet reported for the antibody in this indication.
Among participants who received litifilimab from the outset, 27.2% achieved a CLA-IGA-R erythema score of 0 or 1, denoting clear or almost clear skin, by week 52, up from 19.0% at week 24. On the CLASI-70 measure, 28.8% of patients in that group achieved a 70% or greater reduction in disease activity at week 52, compared with 21.7% at the 24-week point. Participants who crossed over from placebo to litifilimab at week 24 showed onset of benefit within four weeks, and by week 52 some 33.7% of crossover participants had reached the clear or almost clear threshold.
Serious adverse events were recorded in 3.4% of participants during the extended treatment period. The most common adverse events, each reported in at least 5% of the extended-treatment cohort, were nasopharyngitis, influenza and arthralgia.
Mechanism and regulatory status
Litifilimab is a monoclonal antibody targeting blood dendritic cell antigen 2 (BDCA2) receptors on plasmacytoid dendritic cells, which Biogen positions as acting upstream in the inflammatory cascade that drives CLE. The company is evaluating it as a once-monthly subcutaneous injection. In January 2026, the US FDA granted litifilimab Breakthrough Therapy Designation for CLE, a designation that provides more intensive FDA guidance during development and can support a faster review once a biologics licence application is filed.
Daniel Quirk, Chief Medical Officer at Biogen, said the 52-week data "reinforce litifilimab's potential to deliver rapid improvement and demonstrate its durable skin clearance effects" and pointed to the forthcoming Phase 3 readout as the next key milestone. The Phase 3 part of AMETHYST remains blinded and is expected to report in the first half of 2027.
Market context and competitive landscape
CLE affects a significant proportion of people with systemic lupus, yet no targeted therapy has been approved specifically for the condition since the 1950s. The standard of care continues to rely on antimalarial agents such as hydroxychloroquine, topical corticosteroids, and off-label immunosuppressants, all of which carry meaningful tolerability limitations. That therapeutic vacuum is attracting increasing pharmaceutical attention. AstraZeneca's anifrolumab, an anti-type I interferon receptor antibody approved for systemic lupus erythematosus, has been assessed in CLE settings, while a number of other companies are investigating JAK inhibitors and other immunomodulatory approaches in lupus-related skin disease.
Litifilimab's differentiated mechanism, targeting pDCs rather than the broader type I interferon pathway, is central to Biogen's positioning. The Breakthrough Therapy Designation and a prior NEJM publication of Phase 2 LILAC data lend the programme credibility heading into the Phase 3 readout. If the Phase 3 results replicate Phase 2 findings, Biogen would be well placed to file for approval in a condition with no approved targeted option, a regulatory pathway that typically attracts favourable review timelines. Investors will focus on whether the Phase 3 primary endpoint, trial powering, and patient population are sufficiently aligned with the Phase 2 design to make that comparison straightforward.